Intrexon | XON - Equity Capital And Reserves


Intrexon reported $43.17M in Equity Capital and Reserves for its fiscal quarter ending in June of 2024.





Equity Capital And Reserves Change Date
Agenus USD -221.22M 49.89M Mar/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Amgen USD 9.19B 532M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
MannKind USD -59.2M 8.17M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.34B 34.83M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026